{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T07:35:35Z","timestamp":1793172935938,"version":"4.5.0"},"reference-count":61,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","license":[{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,11]]},"abstract":"<jats:p>Local therapy plays a pivotal role in the management of noninfectious uveitis, providing targeted drug delivery with reduced systemic adverse effects. Advances in corticosteroid formulations and delivery routes have significantly improved therapeutic outcomes. Topical corticosteroids remain first-line for anterior uveitis, while periocular and intravitreal injections such as triamcinolone acetonide and dexamethasone implants (Ozurdex\u00ae) are effective for intermediate and posterior disease. Long-acting fluocinolone acetonide implants (Retisert\u00ae, Yutiq\u00ae) offer sustained control for chronic or recurrent cases, though ocular hypertension and cataract formation are common. The introduction of suprachoroidal corticosteroid delivery (Xipere\u00ae) allows precise posterior segment targeting with fewer anterior complications. Nonsteroidal intravitreal agents, including methotrexate and sirolimus, serve as steroid-sparing options, and topical immunomodulators such as cyclosporine and tacrolimus can be rarely used in chronic anterior uveitis. Emerging modalities like intravitreal biologics, nanocarrier systems, and gene-based delivery hold promise for long-term disease modulation. A tailored, evidence-based approach to local therapy can optimize inflammation control and visual outcomes in uveitis management.<\/jats:p>","DOI":"10.4103\/ijo.ijo_2906_25","type":"journal-article","created":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T07:00:09Z","timestamp":1787554809000},"page":"1574-1583","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Local therapy in uveitis: Current concepts and emerging strategies"],"prefix":"10.4103","volume":"74","author":[{"given":"Tanya","family":"Jain","sequence":"first","affiliation":[{"name":"Department of Vitreoretina and Uvea, Dr Shroff\u2019s Charity Eye Hospital, Daryaganj, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pallavi","family":"Goel","sequence":"additional","affiliation":[{"name":"Department of Vitreoretina and Uvea, Dr Shroff\u2019s Charity Eye Hospital, Daryaganj, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manisha","family":"Agarwal","sequence":"additional","affiliation":[{"name":"Department of Vitreoretina and Uvea, Dr Shroff\u2019s Charity Eye Hospital, Daryaganj, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,8,24]]},"reference":[{"key":"R1-20261028","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1111\/ceo.14175","article-title":"The standardisation of uveitis nomenclature (SUN) project","volume":"50","author":"Jabs","year":"2022","journal-title":"Clin Exp Ophthalmol"},{"key":"R2-20261028","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ajo.2005.03.057","article-title":"Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop","volume":"140","author":"Jabs","year":"2005","journal-title":"Am J Ophthalmol"},{"key":"R3-20261028","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1016\/j.ophtha.2006.03.027","article-title":"Impact of macular edema on visual acuity in uveitis","volume":"113","author":"Lardenoye","year":"2006","journal-title":"Ophthalmology"},{"key":"R4-20261028","doi-asserted-by":"crossref","first-page":"6439","DOI":"10.2147\/JIR.S288294","article-title":"Topical anti-inflammatory agents for non-infectious uveitis: Current treatment and perspectives","volume":"15","author":"Balasubramaniam","year":"2022","journal-title":"J Inflamm Res"},{"key":"R5-20261028","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/0002-9394(75)90687-X","article-title":"Comparison of in vitro potency of corticosteroids with ability to raise intraocular pressure","volume":"79","author":"Cantrill","year":"1975","journal-title":"Am J Ophthalmol"},{"key":"R6-20261028","first-page":"107","article-title":"Cycloplegic refraction in optometric practice","volume":"6","author":"Eperjesi","year":"2005","journal-title":"Optometry in Practice"},{"key":"R7-20261028","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s40123-013-0020-5","article-title":"Intraocular pressure effects of common topical steroids for post-cataract inflammation: Are they all the same?","volume":"2","author":"Pleyer","year":"2013","journal-title":"Ophthalmology and Therapy"},{"key":"R8-20261028","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMra050541","article-title":"Anti-inflammatory action of glucocorticoids\u2014new mechanisms for old drugs","volume":"353","author":"Rhen","year":"2005","journal-title":"New England Journal of Medicine"},{"key":"R9-20261028","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ajo.2018.03.027","article-title":"Difluprednate for the treatment of uveitic cystoid macular edema","volume":"191","author":"Schallhorn","year":"2018","journal-title":"American Journal of Ophthalmology"},{"key":"R10-20261028","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1016\/j.ophtha.2009.12.003","article-title":"Risk of cataract development among children with juvenile idiopathic arthritis-related uveitis treated with topical corticosteroids","volume":"117","author":"Thorne","year":"2010","journal-title":"Ophthalmology"},{"key":"R11-20261028","first-page":"407","article-title":"Topical cyclosporine A in the treatment of chronic anterior uveitis","volume":"20","author":"Joseph","year":"2006","journal-title":"Eye (Lond)"},{"key":"R12-20261028","first-page":"961","article-title":"Efficacy of topical cyclosporine A 0.1% in noninfectious anterior uveitis","volume":"37","author":"Ozyol","year":"2017","journal-title":"Int Ophthalmol"},{"key":"R13-20261028","first-page":"744","article-title":"Efficacy of topical tacrolimus for refractory anterior uveitis","volume":"97","author":"Kobayashi","year":"2013","journal-title":"Br J Ophthalmol"},{"key":"R14-20261028","first-page":"109","article-title":"Topical tacrolimus for the treatment of uveitis: Comparative efficacy and safety","volume":"165","author":"Rashid","year":"2016","journal-title":"Am J Ophthalmol"},{"key":"R15-20261028","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1136\/bjo.2008.153874","article-title":"Efficacy and tolerability of interferon alpha treatment in patients with chronic cystoid macular oedema due to non-infectious uveitis","volume":"93","author":"Deuter","year":"2009","journal-title":"Br J Ophthalmol"},{"key":"R16-20261028","doi-asserted-by":"crossref","first-page":"4357","DOI":"10.4103\/ijo.IJO_1450_22","article-title":"Topical interferon therapy in uveitic macular edema","volume":"70","author":"Kawali","year":"2022","journal-title":"Indian J Ophthalmol"},{"key":"R17-20261028","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.ajoc.2018.03.005","article-title":"Topical interferon alpha 2b in the treatment of refractory pseudophakic cystoid macular edema","volume":"10","author":"Maleki","year":"2018","journal-title":"Am J Ophthalmol Case Rep"},{"key":"R18-20261028","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.4103\/ijo.IJO_2704_20","article-title":"Topical interferon - A novel treatment for pseudophakic macular edema","volume":"69","author":"Kawali","year":"2021","journal-title":"Indian J Ophthalmol"},{"key":"R19-20261028","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1080\/09273940802209153","article-title":"Comparison of the efficacy and safety of different methods of posterior subtenon injection","volume":"16","author":"Venkatesh","year":"2008","journal-title":"Ocul Immunol Inflamm"},{"key":"R20-20261028","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1016\/j.ophtha.2014.05.021","article-title":"Periocular corticosteroid injections in uveitis: Effects and complications","volume":"121","author":"Sen","year":"2014","journal-title":"Ophthalmology"},{"key":"R21-20261028","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1097\/ICU.0000000000000651","article-title":"Local treatment of infectious and noninfectious intermediate, posterior, and panuveitis: Current concepts and emerging therapeutics","volume":"31","author":"Thomas","year":"2020","journal-title":"Curr Opin Ophthalmol"},{"key":"R22-20261028","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/j.1442-9071.2004.00902.x","article-title":"Clinical trial to compare efficacy and side-effects of injection of posterior sub-Tenon triamcinolone versus orbital floor methylprednisolone in the management of posterior uveitis","volume":"32","author":"Ferrante","year":"2004","journal-title":"Clin Exp Ophthalmol"},{"key":"R23-20261028","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ophtha.2018.08.021","article-title":"Periocular triamcinolone versus intravitreal triamcinolone versus intravitreal dexamethasone implant for the treatment of uveitic macular edema: The PeriOcular versus INTravitreal corticosteroids for uveitic macular edema (POINT) trial","volume":"126","author":"Thorne","year":"2019","journal-title":"Ophthalmology"},{"key":"R24-20261028","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.ajo.2005.11.050","article-title":"Cataract formation and other complications of intravitreal triamcinolone for macular edema","volume":"141","author":"Thompson","year":"2006","journal-title":"Am J Ophthalmol"},{"key":"R25-20261028","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S0161-6420(02)01969-3","article-title":"Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection","volume":"110","author":"Beer","year":"2003","journal-title":"Ophthalmology"},{"key":"R26-20261028","doi-asserted-by":"crossref","first-page":"e323","DOI":"10.1111\/j.1755-3768.2011.02247.x","article-title":"Repeat intravitreal triamcinolone acetonide injections in uveitic macular oedema","volume":"90","author":"Sallam","year":"2012","journal-title":"Acta Ophthalmol"},{"key":"R27-20261028","doi-asserted-by":"crossref","first-page":"430","DOI":"10.3109\/09273948.2015.1025982","article-title":"Intravitreal triamcinolone injection for uveitic macular edema: A randomized clinical study","volume":"23","author":"Shin","year":"2015","journal-title":"Ocul Immunol Inflamm"},{"key":"R28-20261028","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1001\/archophthalmol.2010.339","article-title":"Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis","volume":"129","author":"Lowder","year":"2011","journal-title":"(HURON study) Arch Ophthalmol"},{"key":"R29-20261028","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1007\/s40123-022-00525-8","article-title":"Real-life efficacy, safety, and use of dexamethasone intravitreal implant in posterior segment inflammation due to non-infectious uveitis (LOUVRE 2 study)","volume":"11","author":"Bodaghi","year":"2022","journal-title":"Ophthalmol Ther"},{"key":"R30-20261028","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.ophtha.2023.04.011","article-title":"Intravitreal therapy for uveitic macular edema\u2014ranibizumab vs methotrexate vs the dexamethasone implant: The MERIT Trial results","volume":"130","author":"Acharya","year":"2023","journal-title":"Ophthalmology"},{"key":"R31-20261028","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s12348-025-00502-9","article-title":"Pharmacotherapy for non-infectious uveitis: Spotlight on phase III clinical trials of locally injected or implanted therapeutics and systemic immunomodulatory drugs","volume":"15","author":"Shields","year":"2025","journal-title":"J Ophthal Inflamm Infect"},{"key":"R32-20261028","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1016\/j.ophtha.2011.07.027","article-title":"Randomized comparison of systemic anti-inflammatory therapy versus fluocinolone acetonide implant for intermediate, posterior, and panuveitis: the multicenter uveitis steroid treatment trial","volume":"118","author":"Kempen","year":"2011","journal-title":"Ophthalmology."},{"key":"R33-20261028","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1001\/archopht.126.9.1191","article-title":"Treatment of posterior uveitis with a fluocinolone acetonide implant: Three-year clinical trial results","volume":"126","author":"Callanan","year":"2008","journal-title":"Arch Ophthalmol"},{"key":"R34-20261028","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40123-014-0027-6","article-title":"Use of the fluocinolone acetonide intravitreal implant for the treatment of noninfectious posterior uveitis: 3-year results of a randomized clinical trial in a predominantly Asian population","volume":"4","author":"Sangwan","year":"2015","journal-title":"Ophthalmol Ther"},{"key":"R35-20261028","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1016\/j.ophtha.2020.04.001","article-title":"Effect of a fluocinolone acetonide insert on recur- rence rates in noninfectious intermediate, posterior, or panuveitis: Three-year results","volume":"127","author":"Jaffe","year":"2020","journal-title":"Ophthalmology"},{"key":"R36-20261028","doi-asserted-by":"crossref","first-page":"100403","DOI":"10.1016\/j.xops.2023.100403","article-title":"The 0.2-\u03bcg\/day fluocinolone acetonide intravitreal implant in chronic noninfectious posterior uveitis: A 3-year ran- domized trial in India","volume":"4","author":"Biswas","year":"2024","journal-title":"Ophthalmol Sci"},{"key":"R37-20261028","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/j.ophtha.2020.01.006","article-title":"Efficacy and safety of suprachoroidal CLS-TA for macular edema secondary to noninfectious uveitis: Phase 3 randomized trial (PEACHTREE)","volume":"127","author":"Yeh","year":"2020","journal-title":"Ophthalmology"},{"key":"R38-20261028","first-page":"1139","article-title":"Extension study of the safety and efficacy of CLS-TA for treatment of macular oedema associated with non-infectious uveitis (MAGNOLIA)","volume":"106","author":"Khurana","year":"2022","journal-title":"Br J Ophthalmol."},{"key":"R39-20261028","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1080\/09273948.2023.2262015","article-title":"Safety and Efficacy of CLS-TA by Anatomic Location of Inflammation: Results from the Phase 3 PEACHTREE Clinical Trial","volume":"32","author":"Shah","year":"2024","journal-title":"Ocul Immunol Inflamm."},{"key":"R40-20261028","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.ophtha.2008.10.033","article-title":"Intraocular methotrexate in the treatment of uveitis and uveitic cystoid macular edema","volume":"116","author":"Taylor","year":"2009","journal-title":"Ophthalmology"},{"key":"R41-20261028","first-page":"862","article-title":"Intravitreal methotrexate in the management of noninfectious uveitis","volume":"97","author":"Taylor","year":"2013","journal-title":"Br J Ophthalmol"},{"key":"R42-20261028","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1016\/j.ophtha.2006.11.028","article-title":"Intravitreal bevacizumab for treatment of uveitic macular edema","volume":"114","author":"Cordero","year":"2007","journal-title":"Ophthalmology"},{"key":"R43-20261028","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.ophtha.2017.12.002","article-title":"PROMETHEUS Study Group. Efficacy and Safety of Ranibizumab 0.5 mg for the Treatment of Macular Edema Resulting from Uncommon Causes: Twelve-Month Findings from PROMETHEUS","volume":"125","author":"Staurenghi","year":"2018","journal-title":"Ophthalmology"},{"key":"R44-20261028","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1097\/IAE.0b013e3181d3758a","article-title":"Intravitreal infliximab for the treatment of sight-threatening chronic non-infectious uveitis","volume":"30","author":"Farvardin","year":"2010","journal-title":"Retina."},{"key":"R45-20261028","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.ajo.2012.03.035","article-title":"Intravitreal infliximab for sight-threatening relapsing uveitis in Beh\u00e7et disease","volume":"154","author":"Markomichelakis","year":"2012","journal-title":"Am J Ophthalmol"},{"key":"R46-20261028","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1869-5760-3-32","article-title":"Ocular tolerability and efficacy of intravitreal and subconjunctival injections of sirolimus in patients with non-infectious uveitis: Primary 6-month results of the SAVE study","volume":"3","author":"Nguyen","year":"2013","journal-title":"J Ophthalmic Inflamm Infect"},{"key":"R47-20261028","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1016\/j.ophtha.2018.06.015","article-title":"Intravitreal Sirolimus for the Treatment of Noninfectious Uveitis: Evolution through Preclinical and Clinical Studies","volume":"125","author":"Nguyen","year":"2018","journal-title":"Ophthalmology."},{"key":"R48-20261028","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1016\/j.ophtha.2016.07.029","article-title":"Sirolimus study Assessing double-masKed Uveitis tReAtment (SAKURA) Study Group. Intravitreal Sirolimus for Noninfectious Uveitis: A Phase III Sirolimus Study Assessing Double-masKed Uveitis TReAtment (SAKURA)","volume":"123","author":"Nguyen","year":"2016","journal-title":"Ophthalmology"},{"key":"R49-20261028","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1001\/jamaophthalmol.2026.0610","article-title":"Interleukin 6 Inhibition With Vamikibart for Uveitic Macular Edema: The Phase 1 DOVETAIL Nonrandomized Clinical Trial","volume":"144","author":"Sharma","year":"2026","journal-title":"JAMA Ophthalmol."},{"key":"R50-20261028","article-title":"MEERKAT and SANDCAT trials of intravitreal vamikibart (NCT05642325, NCT05642312)"},{"key":"R51-20261028","article-title":"APEX Phase 1b Trial of KSI-101 in uveitic macular edema","year":"2024","journal-title":"Press Release"},{"key":"R52-20261028","article-title":"SZN-8143: A trispecific Wnt-modulating IL-6\/VEGF antagonist","year":"2024","journal-title":"Company Pipeline Update"},{"key":"R53-20261028","doi-asserted-by":"crossref","first-page":"6604","DOI":"10.1038\/s41598-018-24545-2","article-title":"Evaluation of subconjunctival liposomal steroids for the treatment of experimental uveitis","volume":"8","author":"Wong","year":"2018","journal-title":"Sci Rep."},{"key":"R54-20261028"},{"key":"R55-20261028","first-page":"394","article-title":"Feasibility of drug delivery to the eye's posterior segment by topical instillation of PLGA nanoparticles","volume":"12","author":"Tahara","year":"2017","journal-title":"Asian J Pharm Sci"},{"key":"R56-20261028","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/nmat3776","article-title":"Stimuli-responsive nanocarriers for drug delivery","volume":"12","author":"Mura","year":"2013","journal-title":"Nat Mater"},{"key":"R57-20261028","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.2147\/OPTH.S364200","article-title":"Ocular Gene Therapy: A Literature Review with Special Focus on Immune and Inflammatory Responses","volume":"16","author":"Ghoraba","year":"2022","journal-title":"Clin Ophthalmol"},{"key":"R58-20261028","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.ymthe.2005.03.018","article-title":"Local administration of an adeno-associated viral vector expressing IL-10 reduces monocyte infiltration and subsequent photoreceptor damage during experimental autoimmune uveitis","volume":"12","author":"Broderick","year":"2005","journal-title":"Mol Ther."},{"key":"R59-20261028","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/s11095-010-0271-y","article-title":"Suprachoroidal drug delivery to the back of the eye using hollow microneedles","volume":"28","author":"Patel","year":"2011","journal-title":"Pharm Res"},{"key":"R60-20261028","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/ceo.14024","article-title":"Suprachoroidal triamcinolone acetonide versus rescue therapies for the treatment of uveitic macular oedema: A post hoc analysis of PEACHTREE","volume":"50","author":"Singer","year":"2022","journal-title":"Clin Exp Ophthalmol"},{"key":"R61-20261028","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1089\/jop.1994.10.69","article-title":"The role of iontophoresis in ocular drug delivery","volume":"10","author":"Sarraf","year":"1994","journal-title":"J Ocul Pharmacol"}],"container-title":["Indian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/IJO.IJO_2906_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T07:00:17Z","timestamp":1793170817000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/IJO.IJO_2906_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,24]]},"references-count":61,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/ijo.ijo_2906_25","relation":{},"ISSN":["0301-4738","1998-3689"],"issn-type":[{"value":"0301-4738","type":"print"},{"value":"1998-3689","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,24]]},"assertion":[{"value":"2025-11-13","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-10","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}